ASGE Presidential Plenary Session highlights the most impactful endoscopy research selected from thousands of submissions to Digestive Disease Week®
Paris and Boston, March 11, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today proudly announces that the CLIMB study (Confocal Laser Endomicroscopy as an IMaging Biomarker, ClinicalTrials.gov ID: NCT03492151) will be presented at the ASGE (American Society for Gastrointestinal Endoscopy) Presidential Plenary Session on Sunday, May 3, 2026, one of the most prestigious sessions of the Digestive Disease Week (DDW) 2026 conference, to be held from May 2 to 5, 2026 in Chicago, Illinois.
This prospective multicenter study (over 500 patients across 14 U.S. centers) led by Dr. Somashekar (Som) Krishna, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center, demonstrates the superiority of EUS-nCLE (Endoscopic Ultrasound-guided needle-based Confocal Laser Endomicroscopy using Cellvizio) for the multimodal diagnosis of pancreatic cystic lesions (PCLs), particularly IPMNs (intraductal papillary mucinous neoplasms), a common type of premalignant or malignant cyst. EUS-nCLE confirms unmatched diagnostic accuracy compared to standard methods (cyst fluid analysis: CEA, amylase, cytology, glucose), thanks to accurate cellular-level visualization which can improve patient management and outcomes.
This selection for the ASGE Presidential Plenary Session highlights the major clinical impact of Cellvizio and positions it as a key tool for the evolution of PCL management.
Dr. Krishna and his team illustrate academic excellence surrounding Cellvizio with 9 accepted works (6 lectures, 3 posters) covering:
- Precise real-time diagnosis (e.g., serous cystadenomas) and reduction of inappropriate surgeries via multimodal approaches;
- Artificial intelligence for automated detection and classification of cysts from EUS-nCLE videos;
- Medico-economic analyses favoring EUS-RFA (Endoscopic Ultrasound-guided Radiofrequency Ablation) vs. surgical resection.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “The selection of the CLIMB study for the ASGE Presidential Plenary Session at DDW 2026 represents a major recognition for Cellvizio and the growing body of clinical evidence supporting its role in the management of pancreatic cysts. The study highlights the unparalleled accuracy as well as multicenter robustness and reproducibility of nCLE in this challenging indication. Since DDW 2025, we have seen strong and increasing demand for Cellvizio in pancreatic cyst evaluation. Through my numerous interactions with physicians across the United States, it is clear that a significant number of interventional endoscopists now view Cellvizio as an essential tool for characterization and risk-stratification of pancreatic cystic lesions. We believe that the visibility of the CLIMB study at DDW 2026 will further accelerate adoption, and we look forward to supporting a growing number of centers integrating Cellvizio into their clinical practice.”
